- Home
- COOP vs MRNA Comparison
COOP vs MRNA Comparison
Compare COOP & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOP
- MRNA
- Stock Information
- Founded
- COOP 1994
- MRNA 2010
- Country
- COOP United States
- MRNA United States
- Employees
- COOP N/A
- MRNA N/A
- Industry
- COOP Finance: Consumer Services
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COOP Finance
- MRNA Health Care
- Exchange
- COOP Nasdaq
- MRNA Nasdaq
- Market Cap
- COOP 12.3B
- MRNA 10.9B
- IPO Year
- COOP N/A
- MRNA 2018
- Fundamental
- Price
- COOP $187.94
- MRNA $24.09
- Analyst Decision
- COOP Buy
- MRNA Hold
- Analyst Count
- COOP 9
- MRNA 19
- Target Price
- COOP $140.13
- MRNA $43.50
- AVG Volume (30 Days)
- COOP 842.8K
- MRNA 8.9M
- Earning Date
- COOP 10-22-2025
- MRNA 08-01-2025
- Dividend Yield
- COOP N/A
- MRNA N/A
- EPS Growth
- COOP N/A
- MRNA N/A
- EPS
- COOP 8.75
- MRNA N/A
- Revenue
- COOP $2,246,000,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- COOP $12.76
- MRNA N/A
- Revenue Next Year
- COOP $10.84
- MRNA $10.17
- P/E Ratio
- COOP $21.46
- MRNA N/A
- Revenue Growth
- COOP 5.69
- MRNA N/A
- 52 Week Low
- COOP $84.15
- MRNA $23.15
- 52 Week High
- COOP $203.42
- MRNA $79.96
- Technical
- Relative Strength Index (RSI)
- COOP 56.43
- MRNA 33.51
- Support Level
- COOP $184.90
- MRNA $26.01
- Resistance Level
- COOP $198.80
- MRNA $25.64
- Average True Range (ATR)
- COOP 7.66
- MRNA 1.12
- MACD
- COOP -1.39
- MRNA -0.22
- Stochastic Oscillator
- COOP 46.26
- MRNA 5.16
About COOP Mr. Cooper Group Inc.
Mr. Cooper Group Inc is a home loan servicer. The company focuses on delivering a variety of servicing and lending products. It has operating segments namely Servicing segment which performs operational activities on behalf of investors or owners of the underlying mortgages and mortgage servicing rights, including collecting and disbursing borrower payments, investor reporting, and customer service, The Originations segment originates residential mortgage loans through a direct-to-consumer channel, which provides refinance options for existing customers, and through a correspondent channel, which purchases or originates loans from mortgage bankers and brokers, and the Corporate segment. The Servicing segment of the company generates maximum revenue.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.